Dasatinib for Chronic Myelogenous Leukemia: A Rapid Health Technology Assessment

OBJECTIVE To analyze the effectiveness, safety and economy of dasatinib in chronic myelogenous leukemia (CML) patients with imatinib-resistant or -intolerant by health technology assessment(HTA), so as to provide currently available best scientific evidence for medication selection. METHODS The study included a systematic literature search for studies published in PubMed, Embase, Cochrane Library, CNKI and Wan Fang databases. Two reviewer independently retrieved, screened and extracted data results based on inclusion and exclusion criteria. RESULTS A HTA report, two systematic review/meta-analysis and nine cost-effective studies were finally included. The use of dasatinib in the treatment of imatinib-resistant or -intolerant CML patients to induce faster and deeper molecular responses and reduce disease progression, so that more patients benefit from it. Besides, the main adverse reactions were neutropenia, thrombocytopenia and so on. Dadatinib and nilotinib could prolong the quality-adjusted life year and had better cost-effectiveness compared with high-dose imatinib. CONCLUSION Dasatinib is an effective, safe in the treatment of imatinib-resistant/-intolerant CML patients. And the economy was better than the high dose of imatinib but worse than nilotinib.